CoChat
Sign Up
Cited by 45Gut microbiota and healthInflammatory Bowel DiseaseOral microbiology and periodontitis research

Development of Inflammatory Bowel Disease Is Linked to a Longitudinal Restructuring of the Gut Metagenome in Mice

Open access
Sharpton, Thomas, Lyalina, Svetlana, Luong, Julie, Pham, Joey, Deal, Emily M., Armour, Courtney, Gaulke, Christopher, Sanjabi, Shomyseh +1 more·2017·mSystems
DOI 10.1128/msystems.00036-17PMC PMC5585689

Published version of a preprint

Open this paper in CoChat — free account

Abstract

IBD patients harbor distinct microbial communities with functional capabilities different from those seen with healthy people. But is this cause or effect? Answering this question requires data on changes in gut microbial communities leading to disease onset. By performing weekly metagenomic sequencing and mixed-effects modeling on an established mouse model of IBD, we identified several functional pathways encoded by the gut microbiome that covary with host immune status. These pathways are novel early biomarkers that may either enable microbes to live inside an inflamed gut or contribute to immune activation in IBD mice. Future work will validate the potential roles of these microbial pathways in host-microbe interactions and human disease. This study was novel in its longitudinal design and focus on microbial pathways, which provided new mechanistic insights into the role of gut microbes in IBD development.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/msystems.00036-17

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 122

  1. [1]Huttenhower C, Kostic AD, Xavier RJ 2014 Inflammatory bowel disease as a model for translating the microbiome. Immunity 40: 843– 854. doi: 10.1016/j.immuni.2014.05.013. 24950204 PMC4135443 · DOI · Paper page
  2. [3]Ayres JS 2016 Cooperative microbial tolerance behaviors in host-microbiota mutualism. Cell 165: 1323– 1331. doi: 10.1016/j.cell.2016.05.049. 27259146 PMC4903080 · DOI
  3. [4]Kostic AD, Xavier RJ, Gevers D 2014 The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 146: 1489– 1499. doi: 10.1053/j.gastro.2014.02.009. 24560869 PMC4034132 · DOI · Paper page
  4. [5]Lees CW, Barrett JC, Parkes M, Satsangi J 2011 New IBD genetics: common pathways with other diseases. Gut 60: 1739– 1753. doi: 10.1136/gut.2009.199679. 21300624 · DOI · Paper page
  5. [6]Wirtz S, Neurath MF 2007 Mouse models of inflammatory bowel disease. Adv Drug Deliv Rev 59: 1073– 1083. doi: 10.1016/j.addr.2007.07.003. 17825455 · DOI
  6. [7]Goodrich JK, Waters JL, Poole AC, Sutter JL, Koren O, Blekhman R, Beaumont M, Van Treuren W, Knight R, Bell JT, Spector TD, Clark AG, Ley RE 2014 Human genetics shape the gut microbiome. Cell 159: 789– 799. doi: 10.1016/j.cell.2014.09.053. 25417156 PMC4255478 · DOI · Paper page
  7. [8]Neuman MG, Nanau RM 2012 Inflammatory bowel disease: role of diet, microbiota, life style. Transl Res 160: 29– 44. doi: 10.1016/j.trsl.2011.09.001. 22687961 · DOI
  8. [9]Bilski J, Mazur-Bialy A, Brzozowski B, Magierowski M, Zahradnik-Bilska J, Wójcik D, Magierowska K, Kwiecien S, Mach T, Brzozowski T 2016 Can exercise affect the course of inflammatory bowel disease? Experimental and clinical evidence. Pharmacol Rep 68: 827– 836. doi: 10.1016/j.pharep.2016.04.009. 27255494 · DOI
  9. [10]Sartor RB, Mazmanian SK 2012 Intestinal microbes in inflammatory bowel diseases. Am J Gastroenterol Suppl 1: 15– 21. doi: 10.1038/ajgsup.2012.4. · DOI · Paper page
  10. [11]Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Dore J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, et al. 2010 A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464: 59– 65. doi: 10.1038/nature08821. 20203603 PMC3779803 · DOI · Paper page
  11. [12]Nielsen HB, Almeida M, Juncker AS, Rasmussen S, Li J, Sunagawa S, Plichta DR, Gautier L, Pedersen AG, Le Chatelier E, Pelletier E, Bonde I, Nielsen T, Manichanh C, Arumugam M, Batto JM, Quintanilha Dos Santos MB, Blom N, Borruel N, Burgdorf KS, Boumezbeur F, Casellas F, Doré J, Dworzynski P, Guarner F, Hansen T, Hildebrand F, Kaas RS, Kennedy S, Kristiansen K, Kultima JR, Léonard P, Levenez F, Lund O, Moumen B, Le Paslier D, Pons N, Pedersen O, Prifti E, Qin J, Raes J, Sorensen S, Tap J, Tims S, Ussery DW, Yamada T, MetaHIT Consortium, Renault P 2014 Identification and assembly of genomes and genetic elements in complex metagenomic samples without using reference genomes. Nat Biotechnol 32: 822– 828. doi: 10.1038/nbt.2939. 24997787 · DOI · Paper page
  12. [13]Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney KL, Ward DV, Reyes JA, Shah SA, LeLeiko N, Snapper SB, Bousvaros A, Korzenik J, Sands BE, Xavier RJ, Huttenhower C 2012 Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 13: R79. doi: 10.1186/gb-2012-13-9-r79. 23013615 PMC3506950 · DOI · Paper page
  13. [14]Ott SJ, Musfeldt M, Wenderoth DF, Hampe J, Brant O, Fölsch UR, Timmis KN, Schreiber S 2004 Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 53: 685– 693. doi: 10.1136/gut.2003.025403. 15082587 PMC1774050 · DOI · Paper page
  14. [15]Dubinsky M, Braun J 2015 Diagnostic and prognostic microbial biomarkers in inflammatory bowel diseases. Gastroenterology 149: 1265– 1274.e3. doi: 10.1053/j.gastro.2015.08.006. 26284597 PMC5302020 · DOI
  15. [16]Nayfach S, Bradley PH, Wyman SK, Laurent TJ, Williams A, Eisen JA, Pollard KS, Sharpton TJ 2015 Automated and accurate estimation of gene family abundance from shotgun metagenomes. PLoS Comput Biol 11: e1004573. doi: 10.1371/journal.pcbi.1004573. 26565399 PMC4643905 · DOI
  16. [17]Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y, Cheng G, Yamasaki S, Saito T, Ohba Y, Taniguchi T, Takeda K, Hori S, Ivanov II, Umesaki Y, Itoh K, Honda K 2011 Induction of colonic regulatory T cells by indigenous Clostridium species. Science 331: 337– 341. doi: 10.1126/science.1198469. 21205640 PMC3969237 · DOI · Paper page
  17. [18]Honda K, Littman DR 2012 The microbiome in infectious disease and inflammation. Annu Rev Immunol 30: 759– 795. doi: 10.1146/annurev-immunol-020711-074937. 22224764 PMC4426968 · DOI · Paper page
  18. [20]David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA, Biddinger SB, Dutton RJ, Turnbaugh PJ 2014 Diet rapidly and reproducibly alters the human gut microbiome. Nature 505: 559– 563. doi: 10.1038/nature12820. 24336217 PMC3957428 · DOI · Paper page
  19. [21]Carmody RN, Gerber GK, Luevano JM Jr, Gatti DM, Somes L, Svenson KL, Turnbaugh PJ 2015 Diet dominates host genotype in shaping the murine gut microbiota. Cell Host Microbe 17: 72– 84. doi: 10.1016/j.chom.2014.11.010. 25532804 PMC4297240 · DOI · Paper page
  20. [22]Rooks MG, Veiga P, Wardwell-Scott LH, Tickle T, Segata N, Michaud M, Gallini CA, Beal C, van Hylckama-Vlieg JE, Ballal SA, Morgan XC, Glickman JN, Gevers D, Huttenhower C, Garrett WS 2014 Gut microbiome composition and function in experimental colitis during active disease and treatment-induced remission. ISME J 8: 1403– 1417. doi: 10.1038/ismej.2014.3. 24500617 PMC4069400 · DOI
  21. [23]Strober W, Fuss IJ, Blumberg RS 2002 The immunology of mucosal models of inflammation. Annu Rev Immunol 20: 495– 549. doi: 10.1146/annurev.immunol.20.100301.064816. 11861611 · DOI
  22. [24]Bouma G, Strober W 2003 The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 3: 521– 533. doi: 10.1038/nri1132. 12876555 · DOI
  23. [25]Hoffmann JC, Pawlowski NN, Kühl AA, Höhne W, Zeitz M 2002–2003 Animal models of inflammatory bowel disease: an overview. Pathobiology 70: 121– 130. 12571415
  24. [26]Mizoguchi A, Mizoguchi E, Bhan AK 2003 Immune networks in animal models of inflammatory bowel disease. Inflamm Bowel Dis 9: 246– 259. doi: 10.1097/00054725-200307000-00005. 12902848 · DOI
  25. [27]Elson CO, Cong Y, McCracken VJ, Dimmitt RA, Lorenz RG, Weaver CT 2005 Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol Rev 206: 260– 276. doi: 10.1111/j.0105-2896.2005.00291.x. 16048554 · DOI
  26. [28]Valatas V, Vakas M, Kolios G 2013 The value of experimental models of colitis in predicting efficacy of biological therapies for inflammatory bowel diseases. Am J Physiol Gastrointest Liver Physiol 305: G763– G785. doi: 10.1152/ajpgi.00004.2013. 23989010 · DOI
  27. [29]Valatas V, Bamias G, Kolios G 2015 Experimental colitis models: insights into the pathogenesis of inflammatory bowel disease and translational issues. Eur J Pharmacol 759: 253– 264. doi: 10.1016/j.ejphar.2015.03.017. 25814256 · DOI
  28. [30]Gorelik L, Flavell RA 2000 Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 12: 171– 181. doi: 10.1016/S1074-7613(00)80170-3. 10714683 · DOI
  29. [31]Yamagiwa S, Gray JD, Hashimoto S, Horwitz DA 2001 A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood. J Immunol 166: 7282– 7289. doi: 10.4049/jimmunol.166.12.7282. 11390478 · DOI
  30. [32]Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM 2003 Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198: 1875– 1886. doi: 10.1084/jem.20030152. 14676299 PMC2194145 · DOI
  31. [33]Schlenner SM, Weigmann B, Ruan Q, Chen Y, von Boehmer H 2012 Smad3 binding to the foxp3 enhancer is dispensable for the development of regulatory T cells with the exception of the gut. J Exp Med 209: 1529– 1535. doi: 10.1084/jem.20112646. 22908322 PMC3428940 · DOI
  32. [34]Selvaraj RK, Geiger TL 2007 A kinetic and dynamic analysis of Foxp3 induced in T cells by TGF-beta. J Immunol 178: 7667– 7677. doi: 10.4049/jimmunol.178.12.7667. 17548603 · DOI
  33. [35]Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF 2004 Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 172: 5149– 5153. doi: 10.4049/jimmunol.172.9.5149. 15100250 · DOI
  34. [36]Huber S, Schramm C, Lehr HA, Mann A, Schmitt S, Becker C, Protschka M, Galle PR, Neurath MF, Blessing M 2004 Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T cells. J Immunol 173: 6526– 6531. doi: 10.4049/jimmunol.173.11.6526. 15557141 · DOI
  35. [37]Marie JC, Letterio JJ, Gavin M, Rudensky AY 2005 TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med 201: 1061– 1067. doi: 10.1084/jem.20042276. 15809351 PMC2213134 · DOI
  36. [38]Battaglia A, Buzzonetti A, Baranello C, Fanelli M, Fossati M, Catzola V, Scambia G, Fattorossi A 2013 Interleukin-21 (IL-21) synergizes with IL-2 to enhance T-cell receptor-induced human T-cell proliferation and counteracts IL-2/transforming growth factor-beta-induced regulatory T-cell development. Immunology 139: 109– 120. doi: 10.1111/imm.12061. 23278180 PMC3634543 · DOI
  37. [39]Molinero LL, Miller ML, Evaristo C, Alegre ML 2011 High TCR stimuli prevent induced regulatory T cell differentiation in a NF-κB-dependent manner. J Immunol 186: 4609– 4617. doi: 10.4049/jimmunol.1002361. 21411734 PMC3544303 · DOI
  38. [40]Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK 2006 Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235– 238. doi: 10.1038/nature04753. 16648838 · DOI · Paper page
  39. [41]Veldhoen M, Stockinger B 2006 TGFbeta1, a “jack of all trades”: the link with pro-inflammatory IL-17-producing T cells. Trends Immunol 27: 358– 361. doi: 10.1016/j.it.2006.06.001. 16793343 · DOI
  40. [42]Li MO, Wan YY, Flavell RA 2007 T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity 26: 579– 591. doi: 10.1016/j.immuni.2007.03.014. 17481928 · DOI
  41. [43]Gutcher I, Donkor MK, Ma Q, Rudensky AY, Flavell RA, Li MO 2011 Autocrine transforming growth factor-beta1 promotes in vivo Th17 cell differentiation. Immunity 34: 396– 408. doi: 10.1016/j.immuni.2011.03.005. 21435587 PMC3690311 · DOI
  42. [44]Manel N, Unutmaz D, Littman DR 2008 The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 9: 641– 649. doi: 10.1038/ni.1610. 18454151 PMC2597394 · DOI
  43. [45]Yang L, Anderson DE, Baecher-Allan C, Hastings WD, Bettelli E, Oukka M, Kuchroo VK, Hafler DA 2008 IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature 454: 350– 352. doi: 10.1038/nature07021. 18469800 PMC2760130 · DOI
  44. [46]Biancheri P, Giuffrida P, Docena GH, MacDonald TT, Corazza GR, Di Sabatino A 2014 The role of transforming growth factor (TGF)-beta in modulating the immune response and fibrogenesis in the gut. Cytokine Growth Factor Rev 25: 45– 55. doi: 10.1016/j.cytogfr.2013.11.001. 24332927 · DOI
  45. [47]Di Giacinto C, Marinaro M, Sanchez M, Strober W, Boirivant M 2005 Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-beta-bearing regulatory cells. J Immunol 174: 3237– 3246. doi: 10.4049/jimmunol.174.6.3237. 15749854 · DOI
  46. [48]Feagins LA 2010 Role of transforming growth factor-beta in inflammatory bowel disease and colitis-associated colon cancer. Inflamm Bowel Dis 16: 1963– 1968. doi: 10.1002/ibd.21281. 20848467 · DOI
  47. [49]Fuss IJ, Boirivant M, Lacy B, Strober W 2002 The interrelated roles of TGF-beta and IL-10 in the regulation of experimental colitis. J Immunol 168: 900– 908. doi: 10.4049/jimmunol.168.2.900. 11777988 · DOI
  48. [50]Harrison OJ, Powrie FM 2013 Regulatory T cells and immune tolerance in the intestine. Cold Spring Harb Perspect Biol 5. doi: 10.1101/cshperspect.a018341. PMC3685893 23818502 · DOI
  49. [51]Izcue A, Coombes JL, Powrie F 2009 Regulatory lymphocytes and intestinal inflammation. Annu Rev Immunol 27: 313– 338. doi: 10.1146/annurev.immunol.021908.132657. 19302043 · DOI
  50. [52]Jarry A, Bossard C, Sarrabayrouse G, Mosnier JF, Laboisse CL 2011 Loss of interleukin-10 or transforming growth factor beta signaling in the human colon initiates a T-helper 1 response via distinct pathways. Gastroenterology 141: 1887– 1896.e1–2. doi: 10.1053/j.gastro.2011.08.002. 21839042 · DOI
  51. [53]Kitani A, Fuss I, Nakamura K, Kumaki F, Usui T, Strober W 2003 Transforming growth factor (TGF)-beta1-producing regulatory T cells induce Smad-mediated interleukin 10 secretion that facilitates coordinated immunoregulatory activity and amelioration of TGF-beta1-mediated fibrosis. J Exp Med 198: 1179– 1188. doi: 10.1084/jem.20030917. 14557415 PMC2194234 · DOI
  52. [54]Weiner HL 2001 Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev 182: 207– 214. doi: 10.1034/j.1600-065X.2001.1820117.x. 11722636 · DOI
  53. [55]Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, Lees CW, Balschun T, Lee J, Roberts R, Anderson CA, Bis JC, Bumpstead S, Ellinghaus D, Festen EM, Georges M, Green T, Haritunians T, Jostins L, Latiano A, Mathew CG, Montgomery GW, Prescott NJ, Raychaudhuri S, Rotter JI, Schumm P, Sharma Y, Simms LA, Taylor KD, Whiteman D, Wijmenga C, Baldassano RN, Barclay M, Bayless TM, Brand S, Büning C, Cohen A, Colombel JF, Cottone M, Stronati L, Denson T, De Vos M, D’Inca R, Dubinsky M, Edwards C, Florin T, Franchimont D, Gearry R, Glas J, Van Gossum A, et al. 2010 Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet 42: 1118– 1125. doi: 10.1038/ng.717. 21102463 PMC3299551 · DOI · Paper page
  54. [56]Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schäffer AA, Noyan F, Perro M, Diestelhorst J, Allroth A, Murugan D, Hätscher N, Pfeifer D, Sykora KW, Sauer M, Kreipe H, Lacher M, Nustede R, Woellner C, Baumann U, Salzer U, Koletzko S, Shah N, Segal AW, Sauerbrey A, Buderus S, Snapper SB, Grimbacher B, Klein C 2009 Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 361: 2033– 2045. doi: 10.1056/NEJMoa0907206. 19890111 PMC2787406 · DOI
  55. [57]McGovern DP, Gardet A, Torkvist L, Goyette P, Essers J, Taylor KD, Neale BM, Ong RT, Lagace C, Li C, Green T, Stevens CR, Beauchamp C, Fleshner PR, Carlson M, D'Amato M, Halfvarson J, Hibberd ML, Lordal M, Padyukov L, Andriulli A, Colombo E, Latiano A, Palmieri O, Bernard EJ, Deslandres C, Hommes DW, de Jong DJ, Stokkers PC, Weersma RK, Sharma Y, Silverberg MS, Cho JH, Wu J, Roeder K, Brant SR, Schumm LP, Duerr RH, Dubinsky MC, Glazer NL, Haritunians T, Ippoliti A, Melmed GY, Siscovick DS, Vasiliauskas EA, Targan SR, Annese V, Wijmenga C, Pettersson S, Rotter JI, et al. 2010 Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet 42: 332– 337. doi: 10.1038/ng.549. 20228799 PMC3087600 · DOI
  56. [58]Naviglio S, Arrigo S, Martelossi S, Villanacci V, Tommasini A, Loganes C, Fabretto A, Vignola S, Lonardi S, Ventura A 2014 Severe inflammatory bowel disease associated with congenital alteration of transforming growth factor beta signaling. J Crohns Colitis 8: 770– 774. doi: 10.1016/j.crohns.2014.01.013. 24486179 · DOI
  57. [59]Kang SS, Bloom SM, Norian LA, Geske MJ, Flavell RA, Stappenbeck TS, Allen PM 2008 An antibiotic-responsive mouse model of fulminant ulcerative colitis. PLoS Med 5: e41. doi: 10.1371/journal.pmed.0050041. 18318596 PMC2270287 · DOI
  58. [60]Fowler SA, Ananthakrishnan AN, Gardet A, Stevens CR, Korzenik JR, Sands BE, Daly MJ, Xavier RJ, Yajnik V 2014 SMAD3 gene variant is a risk factor for recurrent surgery in patients with Crohn’s disease. J Crohns Colitis 8: 845– 851. doi: 10.1016/j.crohns.2014.01.003. 24461721 PMC4237062 · DOI
  59. [61]Cho JH, Brant SR 2011 Recent insights into the genetics of inflammatory bowel disease. Gastroenterology 140: 1704– 1712. doi: 10.1053/j.gastro.2011.02.046. 21530736 PMC4947143 · DOI
  60. [62]Henderson P, van Limbergen JE, Wilson DC, Satsangi J, Russell RK 2011 Genetics of childhood-onset inflammatory bowel disease. Inflamm Bowel Dis 17: 346– 361. doi: 10.1002/ibd.21283. 20839313 · DOI
  61. [63]Ardizzone S, Bevivino G, Monteleone G 2016 Mongersen, an oral Smad7 antisense oligonucleotide, in patients with active Crohn’s disease. Therap Adv Gastroenterol 9: 527– 532. doi: 10.1177/1756283X16636781. PMC4913329 27366221 · DOI
  62. [64]Laudisi F, Dinallo V, Di Fusco D, Monteleone G 2016 Smad7 and its potential as therapeutic target in inflammatory bowel diseases. Curr Drug Metab 17: 303– 306. doi: 10.2174/1389200217666151210130103. 26651974 · DOI
  63. [65]Monteleone G, Boirivant M, Pallone F, MacDonald TT 2008 TGF-beta1 and Smad7 in the regulation of IBD. Mucosal Immunol 1(Suppl 1): S50– S53. doi: 10.1038/mi.2008.55. 19079231 · DOI
  64. [66]Bolker BM, Brooks ME, Clark CJ, Geange SW, Poulsen JR, Stevens MH, White JS 2009 Generalized linear mixed models: a practical guide for ecology and evolution. Trends Ecol Evol 24: 127– 135. doi: 10.1016/j.tree.2008.10.008. 19185386 · DOI · Paper page
  65. [67]Székely GJ, Rizzo ML 2009 Brownian distance covariance. Ann Appl Stat 3: 1236– 1265. doi: 10.1214/09-AOAS312. PMC2889501 20574547 · DOI
  66. [68]Bäumler AJ, Sperandio V 2016 Interactions between the microbiota and pathogenic bacteria in the gut. Nature 535: 85– 93. doi: 10.1038/nature18849. 27383983 PMC5114849 · DOI · Paper page
  67. [69]Byndloss MX, Rivera-Chávez F, Tsolis RM, Bäumler AJ 2017 How bacterial pathogens use type III and type IV secretion systems to facilitate their transmission. Curr Opin Microbiol 35: 1– 7. doi: 10.1016/j.mib.2016.08.007. 27621139 · DOI
  68. [70]Mark Welch JL, Utter DR, Rossetti BJ, Mark Welch DB, Eren AM, Borisy GG 2014 Dynamics of tongue microbial communities with single-nucleotide resolution using oligotyping. Front Microbiol 5: 568. doi: 10.3389/fmicb.2014.00568. 25426106 PMC4224128 · DOI
  69. [71]Rizzo ML, Székely GJ 2010 DISCO analysis: a nonparametric extension of analysis of variance. Ann Appl Stat 4: 1034– 1055. doi: 10.1214/09-AOAS245. · DOI
  70. [73]Prindiville TP, Sheikh RA, Cohen SH, Tang YJ, Cantrell MC, Silva J Jr 2000 Bacteroides fragilis enterotoxin gene sequences in patients with inflammatory bowel disease. Emerg Infect Dis 6: 171– 174. doi: 10.3201/eid0602.000210. 10756151 PMC2640860 · DOI
  71. [74]Rabizadeh S, Rhee KJ, Wu S, Huso D, Gan CM, Golub JE, Wu X, Zhang M, Sears CL 2007 Enterotoxigenic Bacteroides fragilis: a potential instigator of colitis. Inflamm Bowel Dis 13: 1475– 1483. doi: 10.1002/ibd.20265. 17886290 PMC3056612 · DOI
  72. [75]Bloom SM, Bijanki VN, Nava GM, Sun L, Malvin NP, Donermeyer DL, Dunne WM Jr, Allen PM, Stappenbeck TS 2011 Commensal Bacteroides species induce colitis in host-genotype-specific fashion in a mouse model of inflammatory bowel disease. Cell Host Microbe 9: 390– 403. doi: 10.1016/j.chom.2011.04.009. 21575910 PMC3241010 · DOI · Paper page
  73. [76]Conley MN, Wong CP, Duyck KM, Hord N, Ho E, Sharpton TJ 2016 Aging and serum MCP-1 are associated with gut microbiome composition in a murine model. PeerJ 4: e1854. doi: 10.7717/peerj.1854. 27069796 PMC4824877 · DOI
  74. [77]Sartor RB 2008 Microbial influences in inflammatory bowel diseases. Gastroenterology 134: 577– 594. doi: 10.1053/j.gastro.2007.11.059. 18242222 · DOI · Paper page
  75. [78]Kaur N, Chen CC, Luther J, Kao JY 2011 Intestinal dysbiosis in inflammatory bowel disease. Gut Microbes 2: 211– 216. doi: 10.4161/gmic.2.4.17863. 21983063 · DOI
  76. [80]Garrett WS, Gallini CA, Yatsunenko T, Michaud M, DuBois A, Delaney ML, Punit S, Karlsson M, Bry L, Glickman JN, Gordon JI, Onderdonk AB, Glimcher LH 2010 Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis. Cell Host Microbe 8: 292– 300. doi: 10.1016/j.chom.2010.08.004. 20833380 PMC2952357 · DOI · Paper page
  77. [81]Chichlowski M, Westwood GS, Abraham SN, Hale LP 2010 Role of mast cells in inflammatory bowel disease and inflammation-associated colorectal neoplasia in IL-10-deficient mice. PLoS One 5: e12220. doi: 10.1371/journal.pone.0012220. 20808919 PMC2923184 · DOI
  78. [82]Waidmann M, Bechtold O, Frick JS, Lehr HA, Schubert S, Dobrindt U, Loeffler J, Bohn E, Autenrieth IB 2003 Bacteroides vulgatus protects against Escherichia coli-induced colitis in gnotobiotic interleukin-2-deficient mice. Gastroenterology 125: 162– 177. doi: 10.1016/S0016-5085(03)00672-3. 12851881 · DOI · Paper page
  79. [83]Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR 2007 Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 104: 13780– 13785. doi: 10.1073/pnas.0706625104. 17699621 PMC1959459 · DOI · Paper page
  80. [84]Sokol H, Seksik P, Rigottier-Gois L, Lay C, Lepage P, Podglajen I, Marteau P, Doré J 2006 Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm Bowel Dis 12: 106– 111. doi: 10.1097/01.MIB.0000200323.38139.c6. 16432374 · DOI
  81. [85]Peterson DA, Frank DN, Pace NR, Gordon JI 2008 Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. Cell Host Microbe 3: 417– 427. doi: 10.1016/j.chom.2008.05.001. 18541218 PMC2872787 · DOI · Paper page
  82. [86]Sokol H, Seksik P, Furet JP, Firmesse O, Nion-Larmurier I, Beaugerie L, Cosnes J, Corthier G, Marteau P, Doré J 2009 Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 15: 1183– 1189. doi: 10.1002/ibd.20903. 19235886 · DOI · Paper page
  83. [88]Casellas F, Borruel N, Papo M, Guarner F, Antolín M, Videla S, Malagelada JR 1998 Antiinflammatory effects of enterically coated amoxicillin-clavulanic acid in active ulcerative colitis. Inflamm Bowel Dis 4: 1– 5. doi: 10.1097/00054725-199802000-00001. 9552221 · DOI
  84. [89]Rietdijk ST, D’Haens GR 2013 Recent developments in the treatment of inflammatory bowel disease. J Dig Dis 14: 282– 287. doi: 10.1111/1751-2980.12048. 23419117 · DOI
  85. [90]Gusils C, Morata V, González S 2004 Determination of bacterial adhesion to intestinal mucus. Methods Mol Biol 268: 411– 415. doi: 10.1385/1-59259-766-1:411. 15156051 · DOI
  86. [91]Murch SH, MacDonald TT, Walker-Smith JA, Levin M, Lionetti P, Klein NJ 1993 Disruption of sulphated glycosaminoglycans in intestinal inflammation. Lancet 341: 711– 714. doi: 10.1016/0140-6736(93)90485-Y. 8095623 · DOI
  87. [92]Benjdia A, Martens EC, Gordon JI, Berteau O 2011 Sulfatases and a radical S-adenosyl-l-methionine (AdoMet) enzyme are key for mucosal foraging and fitness of the prominent human gut symbiont, Bacteroides thetaiotaomicron. J Biol Chem 286: 25973– 25982. doi: 10.1074/jbc.M111.228841. 21507958 PMC3138274 · DOI
  88. [93]Ulmer JE, Vilén EM, Namburi RB, Benjdia A, Beneteau J, Malleron A, Bonnaffé D, Driguez PA, Descroix K, Lassalle G, Le Narvor C, Sandström C, Spillmann D, Berteau O 2014 Characterization of glycosaminoglycan (GAG) sulfatases from the human gut symbiont Bacteroides thetaiotaomicron reveals the first GAG-specific bacterial endosulfatase. J Biol Chem 289: 24289– 24303. doi: 10.1074/jbc.M114.573303. 25002587 PMC4148858 · DOI
  89. [94]Heuston S, Begley M, Gahan CG, Hill C 2012 Isoprenoid biosynthesis in bacterial pathogens. Microbiology 158: 1389– 1401. doi: 10.1099/mic.0.051599-0. 22466083 · DOI
  90. [95]Pereira C, Grácio D, Teixeira JP, Magro F 2015 Oxidative stress and DNA damage: implications in inflammatory bowel disease. Inflamm Bowel Dis 21: 2403– 2417. doi: 10.1097/MIB.0000000000000506. 26193347 · DOI
  91. [96]Steiner TS 2007 How flagellin and Toll-like receptor 5 contribute to enteric infection. Infect Immun 75: 545– 552. doi: 10.1128/IAI.01506-06. 17118981 PMC1828527 · DOI · Paper page
  92. [97]Cullender TC, Chassaing B, Janzon A, Kumar K, Muller CE, Werner JJ, Angenent LT, Bell ME, Hay AG, Peterson DA, Walter J, Vijay-Kumar M, Gewirtz AT, Ley RE 2013 Innate and adaptive immunity interact to quench microbiome flagellar motility in the gut. Cell Host Microbe 14: 571– 581. doi: 10.1016/j.chom.2013.10.009. 24237702 PMC3920589 · DOI
  93. [98]Michielan A, D’Incà R 2015 Intestinal permeability in inflammatory bowel disease: pathogenesis, clinical evaluation, and therapy of leaky gut. Mediators Inflamm 2015: 628157. doi: 10.1155/2015/628157. 26582965 PMC4637104 · DOI · Paper page
  94. [99]Nugent SG, Kumar D, Rampton DS, Evans DF 2001 Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut 48: 571– 577. doi: 10.1136/gut.48.4.571. 11247905 PMC1728243 · DOI
  95. [100]Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung YM, Wu Y, Schauer P, Smith JD, Allayee H, Tang WH, DiDonato JA, Lusis AJ, Hazen SL 2011 Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472: 57– 63. doi: 10.1038/nature09922. 21475195 PMC3086762 · DOI · Paper page
  96. [101]Schicho R, Marsche G, Storr M 2015 Cardiovascular complications in inflammatory bowel disease. Curr Drug Targets 16: 181– 188. doi: 10.2174/1389450116666150202161500. 25642719 PMC4366573 · DOI
  97. [102]Andersen NN, Jess T 2014 Risk of cardiovascular disease in inflammatory bowel disease. World J Gastrointest Pathophysiol 5: 359– 365. doi: 10.4291/wjgp.v5.i3.359. 25133036 PMC4133533 · DOI
  98. [103]Gootenberg DB, Paer JM, Luevano JM, Kwon DS 2017 HIV-associated changes in the enteric microbial community: potential role in loss of homeostasis and development of systemic inflammation. Curr Opin Infect Dis 30: 31– 43. doi: 10.1097/QCO.0000000000000341. 27922852 PMC5325247 · DOI
  99. [104]Trøseid M, Manner IW, Pedersen KK, Haissman JM, Kvale D, Nielsen SD 2014 Microbial translocation and cardiometabolic risk factors in HIV infection. AIDS Res Hum Retroviruses 30: 514– 522. doi: 10.1089/aid.2013.0280. 24521167 PMC4046217 · DOI
  100. [105]Nobles CL, Maresso AW 2011 The theft of host heme by Gram-positive pathogenic bacteria. Metallomics 3: 788– 796. doi: 10.1039/c1mt00047k. 21725569 · DOI
  101. [107]Gasche C, Lomer MC, Cavill I, Weiss G 2004 Iron, anaemia, and inflammatory bowel diseases. Gut 53: 1190– 1197. doi: 10.1136/gut.2003.035758. 15247190 PMC1774131 · DOI
  102. [108]Kaitha S, Bashir M, Ali T 2015 Iron deficiency anemia in inflammatory bowel disease. World J Gastrointest Pathophysiol 6: 62– 72. doi: 10.4291/wjgp.v6.i3.62. 26301120 PMC4540708 · DOI
  103. [109]Williams HR, Cox IJ, Walker DG, North BV, Patel VM, Marshall SE, Jewell DP, Ghosh S, Thomas HJ, Teare JP, Jakobovits S, Zeki S, Welsh KI, Taylor-Robinson SD, Orchard TR 2009 Characterization of inflammatory bowel disease with urinary metabolic profiling. Am J Gastroenterol 104: 1435– 1444. doi: 10.1038/ajg.2009.175. 19491857 · DOI
  104. [110]Williams HR, Cox IJ, Walker DG, Cobbold JF, Taylor-Robinson SD, Marshall SE, Orchard TR 2010 Differences in gut microbial metabolism are responsible for reduced hippurate synthesis in Crohn’s disease. BMC Gastroenterol 10: 108. doi: 10.1186/1471-230X-10-108. 20849615 PMC2954941 · DOI
  105. [111]Radogna F, Diederich M, Ghibelli L 2010 Melatonin: a pleiotropic molecule regulating inflammation. Biochem Pharmacol 80: 1844– 1852. doi: 10.1016/j.bcp.2010.07.041. 20696138 · DOI · Paper page
  106. [112]Paulose JK, Wright JM, Patel AG, Cassone VM 2016 Human gut bacteria are sensitive to melatonin and express endogenous circadian rhythmicity. PLoS One 11: e0146643. doi: 10.1371/journal.pone.0146643. 26751389 PMC4709092 · DOI
  107. [113]Paiva CN, Bozza MT 2014 Are reactive oxygen species always detrimental to pathogens? Antioxid Redox Signal 20: 1000– 1037. doi: 10.1089/ars.2013.5447. 23992156 PMC3924804 · DOI
  108. [114]Preston A, Mandrell RE, Gibson BW, Apicella MA 1996 The lipooligosaccharides of pathogenic gram-negative bacteria. Crit Rev Microbiol 22: 139– 180. doi: 10.3109/10408419609106458. 8894399 · DOI
  109. [115]Cárdenas L, Domínguez J, Santana O, Quinto C 1996 The role of the nodI and nodJ genes in the transport of Nod metabolites in Rhizobium etli. Gene 173: 183– 187. doi: 10.1016/0378-1119(96)00166-7. 8964496 · DOI
  110. [116]Vázquez M, Santana O, Quinto C 1993 The NodL and NodJ proteins from Rhizobium and Bradyrhizobium strains are similar to capsular polysaccharide secretion proteins from gram-negative bacteria. Mol Microbiol 8: 369– 377. doi: 10.1111/j.1365-2958.1993.tb01580.x. 8316086 · DOI
  111. [117]Funderburg NT, Stubblefield Park SR, Sung HC, Hardy G, Clagett B, Ignatz-Hoover J, Harding CV, Fu P, Katz JA, Lederman MM, Levine AD 2013 Circulating CD4(+) and CD8(+) T cells are activated in inflammatory bowel disease and are associated with plasma markers of inflammation. Immunology 140: 87– 97. doi: 10.1111/imm.12114. 23600521 PMC3809709 · DOI
  112. [119]Human Microbiome Project Consortium 2012 Structure, function and diversity of the healthy human microbiome. Nature 486: 207– 214. doi: 10.1038/nature11234. 22699609 PMC3564958 · DOI · Paper page
  113. [121]Schmieder R, Edwards R 2011 Quality control and preprocessing of metagenomic datasets. Bioinformatics 27: 863– 864. doi: 10.1093/bioinformatics/btr026. 21278185 PMC3051327 · DOI
  114. [123]Hyatt D, Chen GL, Locascio PF, Land ML, Larimer FW, Hauser LJ 2010 Prodigal: prokaryotic gene recognition and translation initiation site identification. BMC Bioinformatics 11: 119. doi: 10.1186/1471-2105-11-119. 20211023 PMC2848648 · DOI
  115. [124]Zhao Y, Tang H, Ye Y 2012 RAPSearch2: a fast and memory-efficient protein similarity search tool for next-generation sequencing data. Bioinformatics 28: 125– 126. doi: 10.1093/bioinformatics/btr595. 22039206 PMC3244761 · DOI
  116. [125]Nayfach S, Pollard KS 2015 Average genome size estimation improves comparative metagenomics and sheds light on the functional ecology of the human microbiome. Genome Biol 16: 51. doi: 10.1186/s13059-015-0611-7. 25853934 PMC4389708 · DOI
  117. [128]Chen J, Bittinger K, Charlson ES, Hoffmann C, Lewis J, Wu GD, Collman RG, Bushman FD, Li H 2012 Associating microbiome composition with environmental covariates using generalized UniFrac distances. Bioinformatics 28: 2106– 2113. doi: 10.1093/bioinformatics/bts342. 22711789 PMC3413390 · DOI
  118. [129]Yarza P, Ludwig W, Euzéby J, Amann R, Schleifer KH, Glöckner FO, Rosselló-Móra R 2010 Update of the All-Species Living Tree Project based on 16S and 23S rRNA sequence analyses. Syst Appl Microbiol 33: 291– 299. doi: 10.1016/j.syapm.2010.08.001. 20817437 · DOI
  119. [130]Zhang Y 2013 Likelihood-based and Bayesian methods for Tweedie compound Poisson linear mixed models. Stat Comput 23: 743– 757. doi: 10.1007/s11222-012-9343-7. · DOI
  120. [131]Ye Y, Doak TG 2009 A parsimony approach to biological pathway reconstruction/inference for genomes and metagenomes. PLoS Comput Biol 5: e1000465. doi: 10.1371/journal.pcbi.1000465. 19680427 PMC2714467 · DOI
  121. [132]Hejblum BP, Skinner J, Thiébaut R 2015 Time course gene set analysis for longitudinal gene expression data. PLoS Comput Biol 11: e1004310. doi: 10.1371/journal.pcbi.1004310. 26111374 PMC4482329 · DOI
  122. [133]Wu S, Wu H 2013 More powerful significant testing for time course gene expression data using functional principal component analysis approaches. BMC Bioinformatics 14: 6. doi: 10.1186/1471-2105-14-6. 23323795 PMC3617096 · DOI

Cited by

Sorted by citations

Authors
Sharpton, T., Lyalina, S., Luong, J., Pham, J., Deal, E. M., Armour, C., Gaulke, C., Sanjabi, S., & Pollard, K. S.
Affiliations
  • Oregon State University (US)
  • Gladstone Institutes (US)
Corresponding author
Pollard, Katherine S.
ORCID
Venue
mSystems
Publisher
American Society for Microbiology
Published
2017-10-31
Volume
2
Issue
5
ISSN
2379-5077 (ISSN-L)
DOI
10.1128/msystems.00036-17
PMC
PMC5585689
OpenAlex
W2951361249
Cited by
45
References
7
Citations by year
2026: 1 · 2025: 2 · 2024: 2 · 2023: 6 · 2022: 5 · 2021: 8 · 2020: 8 · 2019: 7 · 2018: 6
FWCI
2.35
Type
journal article
Language
en
Open access
Licence
Locations
  • mSystems (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
NIH/NIAID (AI108953)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
  • Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
Keywords
inflammatory bowel disease, gut microbiota, metagenome, microbial functional pathways, host-microbe interactions, immune activation, disease biomarkers, mixed models

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review